Related by context. All words. (Click for frequent words.) 76 events SAEs 76 laboratory abnormalities 75 treatment emergent adverse 74 Adverse events 73 AEs 72 discontinuations due 72 TEAEs 71 lopinavir r arm 71 hematologic toxicity 71 ALT flares 69 mg BID 69 REYATAZ r arm 68 ACTEMRA TM 68 nasopharyngitis 68 oxycodone CR 68 leukopenia 68 CANCIDAS 68 peripheral sensory neuropathy 67 leucopenia 67 pyrexia mucositis sepsis febrile 67 mcg QD 67 mg QD 67 febrile neutropenia 67 lymphopenia 67 DLTs 66 hypomagnesemia 66 incidence ≥ 66 adverse reactions observed 66 mcg BID 66 FluCAM arm 66 patients receiving ERBITUX 65 RLAI 65 gastrointestinal toxicities 65 hematologic adverse 65 neutropenia dehydration dyspnea 65 placebo controlled clinical trials 65 FOLPI 65 solifenacin 65 posaconazole 65 diarrhea nausea fatigue 65 PREZISTA r 65 tolvaptan 65 chlorambucil 65 desvenlafaxine succinate 65 adverse reactions incidence 65 Hypersensitivity reactions 65 neutropaenia 65 receiving INTRON 65 events TEAEs 65 headache nasopharyngitis 65 events MACE 65 FOLFIRI 65 APTIVUS r 65 ARCOXIA 65 SAEs 64 Treatment discontinuations due 64 definite stent thrombosis 64 thromboembolic events 64 Discontinuations 64 QTc prolongation 64 superficial edema 64 treatment emergent AEs 64 mg dose 64 ARCALYST ® 64 8mg/kg 64 HBeAg negative patients 64 pruritis 64 TYSABRI treated 64 dapagliflozin plus 64 comparator arm 64 gout flares 64 dose limiting toxicities 64 arthralgia 64 PREZISTA r arm 64 certolizumab 64 pyrexia 64 #mg/day [001] 64 severe neutropenia 64 discontinuations 64 ocular adverse 64 hypophosphatemia 63 PREZISTA ritonavir 63 mg kg dose 63 mg ustekinumab 63 mcg albinterferon alfa 2b 63 Peripheral edema 63 ACR# ACR# 63 dosage regimens 63 DOXIL 63 mcg kg REBETOL 63 nasopharyngitis headache 63 adalimumab 63 mg TID 63 risperidone Risperdal 63 Serious adverse reactions 63 peripheral edema 63 plus methotrexate 63 neutropenia thrombocytopenia 63 ALVESCO 63 zolmitriptan 63 hypokalemia 63 EXJADE 63 achieved PASI 63 mycophenolate mofetil 63 Keppra R 63 evaluable subjects 63 ACTEMRA 63 tapentadol ER 63 adjunctive ABILIFY 63 neutropenia 63 adverse reactions occurring 63 adjunctive placebo 62 lopinavir r 62 ATACAND 62 rizatriptan 62 severe hypersensitivity reactions 62 transaminase elevations 62 mcg doses 62 infusion reactions 62 diarrhea nausea vomiting 62 4mg/kg 62 AGILECT R 62 hematological adverse 62 virologic response 62 neutropenia febrile neutropenia 62 generalized edema 62 teriflunomide 62 GSK# [001] 62 stomatitis 62 oral olanzapine 62 #mg BID [001] 62 Infusion Reactions Severe 62 LEXIVA r 62 R# #mg BID 62 MIRCERA 62 concomitant medications 62 cytogenetic response 62 plus dexamethasone 62 unresectable HCC 62 docetaxel chemotherapy 62 placebo dexamethasone 62 achieved ACR# 62 fatigue asthenia 62 HBeAg positive patients 62 Q2W 62 FOLFOX4 62 hypoglycemic events 62 myelosuppression 62 hypersensitivity reactions 62 linaclotide treated 62 achieved statistical significance 62 biologic DMARD 62 thrombocytopenia 62 CIMZIA ™ 61 CIMZIA TM 61 arterial thromboembolic events 61 receiving VICTRELIS 61 ABC/3TC 61 composite endpoint 61 asthenia 61 myalgia arthralgia 61 prucalopride 61 receiving golimumab 61 paresthesias 61 INVEGA ® 61 dose regimens 61 HBeAg positive 61 chills fever headache 61 FOLFOX 61 ARIXTRA 61 virologic failure 61 acneform rash 61 ARB telmisartan 61 MACCE 61 PEG Interferon alfa 61 LEXIVA 61 evaluable 61 XIENCE V PROMUS Stent 61 anaphylactoid reactions 61 hematologic toxicities 61 dosing cohorts 61 doxorubicin cyclophosphamide 61 INTRON 61 mg m² 61 placebo controlled studies 61 cerebrovascular events 61 pruritus 61 apremilast 61 elotuzumab 61 constipation nausea 61 intravenous bisphosphonates 61 doxazosin 61 experienced hypomagnesemia 61 Serious ocular 61 Toxicities 61 non hematological toxicities 61 5-FU/LV 61 budesonide pMDI 61 levetiracetam 61 hypocalcemia 61 REMICADE ® 61 TORISEL 61 nadroparin 61 headache nausea diarrhea 61 HCV RESPOND 2 61 hypersensitivity reaction 61 TNF antagonist 61 dose cohorts 61 MCyR 61 QTc 61 MADRS score 61 adverse reactions ≥ 60 pegylated interferon alfa 2b 60 active comparator 60 hypercalcemia 60 tapentadol IR 60 elevated ALT 60 insulin detemir 60 â ‰ ¥ 60 Angioedema 60 Peg IFN 60 bosentan 60 Neutropenia 60 KRAS mutations occur 60 HBeAg seroconversion 60 severe exacerbations 60 #mg BID [003] 60 INCB# [003] 60 HCV SPRINT 60 ropivacaine 60 Discontinuations due 60 RRMS patients 60 hematologic adverse reactions 60 limiting toxicity 60 stage IIIB 60 tocilizumab 60 VFEND 60 mcg Albuferon 60 Flu Cy 60 relapsed MM 60 mitoxantrone 60 #mg QD [002] 60 administered subcutaneously 60 hematological toxicity 60 hematological toxicities 60 Dermatologic toxicities 60 myalgia 60 plus gemcitabine 60 headache abdominal pain 60 hypotension 60 peginterferon alfa 2b 60 oral rivaroxaban 60 tamsulosin 60 saline placebo 60 AGILECT ® 60 ORENCIA 60 aminotransferase elevations greater 60 hepatotoxicity 60 prednisone prednisolone 60 intra articular injection 60 mg BID dose 60 lacosamide 60 atazanavir ritonavir 60 tolterodine ER 60 CIMZIA TM certolizumab pegol 60 patients evaluable 60 ribavirin RBV 60 conjunctival hyperemia 60 angioedema 60 tolerability profiles 60 quetiapine 60 BARACLUDE ® 60 EDSS scores 60 OAB symptoms 60 Perforomist Inhalation Solution 60 efalizumab 60 IBS C 60 headache diarrhea nausea 60 TMC# r 60 prednisone prednisolone plus 60 ACR# response 59 CCyR 59 placebo controlled clinical 59 neutropenia anemia 59 piperacillin tazobactam 59 Pegasys ® 59 ritonavir boosted 59 MYCAMINE 59 Fludara 59 REMINYL ® 59 icatibant 59 TAXUS Stent 59 #mg doses [002] 59 REVLIMID ® 59 recurrent VTE 59 tenofovir emtricitabine 59 mucositis 59 TDF FTC 59 Pharmacokinetic parameters 59 ascending doses 59 divalproex sodium 59 lamotrigine 59 Keppra ® 59 DMARD therapy 59 PEGINTRON TM 59 pramipexole 59 Stent thrombosis 59 alpha interferons 59 Tolerability 59 octreotide LAR 59 ketoconazole 59 venlafaxine XR 59 Psoriasis Area 59 intravitreal injections 59 placebo p = 59 FOLFIRI alone 59 oral diclofenac 59 intraocular inflammation 59 telaprevir dosing 59 Adalimumab 59 primary generalized tonic 59 metastatic RCC 59 ribavirin therapy 59 Treatment emergent adverse 59 corticosteroid therapy 59 nonvertebral fractures 59 morphometric vertebral fractures 59 dexamethasone Decadron 59 anticholinergics 59 alfa 2a 59 mg Proellex 59 valacyclovir 59 randomized #:#:# 59 somatostatin analog 59 receptor tyrosine kinase inhibitor 59 decitabine 59 ibandronate 59 refractory gout 59 somnolence dizziness 59 mg/# h 59 DMARD 59 triamcinolone 59 PRECiSE 59 rFVIIa 59 symptomatic VTE 59 6R BH4 59 tipranavir r 59 receiving XGEVA 59 tegaserod 59 CYPHER Stent 59 TNF antagonists 59 eosinophilic asthma 59 nausea somnolence 59 NATRECOR R 59 haloperidol Haldol 59 alanine aminotransferase 59 salmeterol HFA MDI 59 cytopenias 59 Hematologic 59 antiarrhythmic drugs 59 ximelagatran 59 dyskinesia PD LID 59 moderate renal impairment 59 idraparinux 59 VELCADE melphalan 59 gastrointestinal perforation 59 virological failure 59 Index CDAI 59 RLS symptoms 59 adefovir treated 59 doripenem 59 mg qd 59 #mg/m# [001] 59 pimecrolimus cream 59 salmeterol fluticasone 59 EURIDIS 59 urate lowering therapy 59 interferon alfa 2b 59 ORENCIA ® 59 diabetic neuropathic pain 59 O PPDS 59 REYATAZ r 59 BENICAR HCT 59 plus OBT 59 XGEVA 59 timolol 59 GOUT 59 flutamide 59 Febrile neutropenia 59 infection nasopharyngitis 59 mg/m2/day 59 VIIBRYD 59 BUPHENYL 59 ULORIC 59 dosing cohort 59 haematologic 59 melphalan prednisone 59 hepatic impairment 59 tiotropium 59 FOLFOX4 alone 59 DAS# scores 59 pruritus itching 59 #mg BID [002] 59 highly emetogenic 59 severe renal impairment 59 n = 59 Elitek 58 mcg kg 58 VIRAMUNE XR 58 Baseline characteristics 58 non squamous NSCLC 58 venlafaxine Effexor 58 non splenectomized 58 urinary N telopeptide 58 oxycodone IR 58 abacavir lamivudine 58 sunitinib malate 58 thrombocytopenia neutropenia 58 cinacalcet 58 Adverse reactions 58 ZYVOX 58 P = .# 58 diarrhea vomiting nausea 58 enalapril 58 briakinumab 58 Teriflunomide 58 venlafaxine ER 58 beclomethasone dipropionate 58 mg/m2 dose 58 extrapyramidal symptoms 58 mometasone furoate 58 transaminases 58 cardiac toxicity 58 ertapenem 58 ONGLYZA 58 etanercept 58 COZAAR 58 fluconazole 58 caspofungin 58 Primary endpoints 58 Myelosuppression 58 YERVOY 58 PRADAXA 58 PRADAXA #mg 58 INTELENCE 58 Hematologic toxicity 58 secondary efficacy endpoints 58 double blinded placebo 58 label dose titration 58 INVANZ 58 partial remissions 58 docetaxel Taxotere ® 58 timepoints 58 CAELYX 58 dermatologic toxicities 58 oral allopurinol 58 NEUPOGEN 58 PASI scores 58 nephrotoxicity 58 oral FTY# 58 rotigotine 58 NOXAFIL 58 Serious Adverse Events 58 μg dose 58 irbesartan 58 Pharmacokinetics PK 58 PROMACTA 58 daunorubicin 58 ALT elevations 58 stent thromboses 58 EDEMA3 58 ciclesonide 58 low dose cytarabine 58 pericardial effusion 58 INFERGEN 58 Serious AEs 58 L PPDS 58 ketorolac 58 vandetanib 58 FOLPI regimen 58 Thrombolysis 58 darunavir ritonavir 58 fluticasone furoate 58 ritonavir boosted atazanavir 58 Vfend 58 pancytopenia 58 ONGLYZA saxagliptin 58 aminotransferases 58 oral vancomycin 58 CONCERTA 58 diuretic chlorthalidone 58 Ophena TM 58 nicardipine 58 peginterferon alfa 58 infliximab monotherapy 58 Zometa hazard 58 virological response 58 nonrandomized 58 LAMICTAL 58 advanced adenomas 58 non metastatic osteosarcoma 58 adverse reactions 58 PREMPRO 58 voriconazole 58 angioneurotic edema 58 gout flare 58 evaluable patients 58 mg RDEA# 58 COPD exacerbation 58 PEGASYS ® 58 JANUVIA 58 BYSTOLIC 58 thromboembolic 58 aspartate aminotransferase AST 58 ARCALYST 58 ecchymosis 58 mcg linaclotide 58 ARICEPT 58 systemic absorption 58 mesalamine 58 analgesic efficacy 58 REYATAZ ritonavir 58 LVEF 58 dose cohort 58 EFFEXOR XR 58 fingolimod 58 spontaneous bowel movements 58 dyspareunia 58 tirofiban 58 Mg Usa 58 PREZISTA rtv 58 Pred Forte 58 del 5q MDS 58 Phase III placebo controlled 58 GERD symptom 58 oxcarbazepine 58 Traficet EN 58 metformin monotherapy 58 postmenopausal osteoporotic women 58 NATRECOR ® 58 ethambutol 58 sulfasalazine 58 #mg/day [002] 58 NYHA Class II 58 undetectable HBV DNA 58 familial amyloidotic polyneuropathy FAP 58 imatinib resistant 58 RAPAFLO R 58 receiving PEGINTRON 58 MoxDuo TM IR 57 receiving VELCADE 57 mg doses 57 μg kg 57 dasatinib Sprycel ® 57 valsartan amlodipine 57 recurrent glioblastoma multiforme 57 nadolol 57 rilpivirine 57 Lamictal XR 57 antiepileptics 57 LPV r 57 Syndrome RLS 57 lumbar spine BMD 57 DMARDS 57 renal impairment 57 amoxicillin clavulanate 57 certolizumab pegol 57 montelukast 57 tacrolimus ointment 57 humanized interleukin 6 57 Doxil ® 57 bone marrow reticulin deposition 57 IV bolus 57 NLX P# 57 Secondary endpoints 57 Paxil paroxetine 57 LEVAQUIN ® 57 nonfatal MI 57 paroxetine Paxil 57 RAPTIVA 57 teriparatide 57 #mg dose [002] 57 receiving ISENTRESS 57 BENICAR 57 plus prednisone prednisolone 57 fluoxetine paroxetine 57 Oral Fingolimod 57 anemia neutropenia 57 GEMZAR 57 LIALDA 57 rilonacept 57 BRIM2 57 alfuzosin 57 ipsilateral stroke 57 zonisamide SR 57 lenalidomide dexamethasone 57 baseline HbA1c 57 lumbar spine bone 57 dasatinib 57 oral Hycamtin 57 plus prednisone 57 dizziness nausea diarrhea 57 unstable angina pectoris 57 QTcF 57 lumiracoxib 57 TYGACIL 57 antiepileptic drug 57 dose titration 57 metastatic GIST 57 x ULN 57 SVR# 57 oral levofloxacin 57 sertraline Zoloft 57 β blockers 57 superficial bladder cancer 57 endophthalmitis 57 ruboxistaurin 57 hepatic adverse 57 liver transaminases 57 ISENTRESS 57 plus ribavirin 57 latrepirdine 57 clozapine Clozaril 57 sirolimus 57 myelodysplastic myeloproliferative diseases 57 alpha blocker 57 clomipramine 57 intermittent dosing 57 progressive PsA 57 interferon alfa 57 stage IIIb IV 57 Acetate Rectal Suppositories 57 lopinavir ritonavir 57 delayed CINV 57 dysuria 57 heavily pretreated patients 57 Hypocalcemia 57 XIENCE V demonstrated 57 ZOMIG 57 albinterferon alfa 2b 57 visilizumab 57 ziprasidone Geodon 57 benazepril 57 delayed onset CINV 57 sirolimus eluting stent 57 primary hypercholesterolemia 57 brand ciclesonide HFA 57 inflammatory lesions 57 ARIMIDEX 57 renal insufficiency 57 mg eq 57 EVIZON 57 Betaferon ® 57 EDEMA4 trial 57 fluticasone salmeterol 57 limiting toxicity DLT 57 mg Lucentis 57 extrapyramidal disorder 57 venous thromboembolic events 57 IXEMPRA 57 INVEGA 57 PEGINTRON 57 ancrod 57 baminercept 57 neurologic symptoms 57 ≥ 57 hemodynamically significant 57 PegIFN RBV 57 sensory neuropathy 57 citalopram 57 BoNTA 57 hepatic enzymes 57 olanzapine LAI 57 tolerability 57 thromboembolic complications 57 esomeprazole 57 IFN α 57 HbA 1c levels 57 LYSTEDA 57 lamivudine refractory patients 57 AIR CF1 57 primidone 57 #mg dose [003] 57 glimepiride 57 Events MACE 57 myopathy rhabdomyolysis 57 antiepileptic drugs AEDs 57 pomalidomide 57 didanosine associated 57 dalteparin 57 gastrointestinal adverse reactions 57 paclitaxel eluting stents 57 RoACTEMRA 57 renal toxicity 57 evaluating tivozanib 57 placebo 57 Elagolix 57 Atacand 57 peginterferon alfa 2a 57 Monotherapy 57 concomitant AEDs 57 clobazam 57 dosed orally 57 Crohn Disease Activity 57 budesonide formoterol 57 refractory NSCLC 57 plus COPEGUS 57 Apidra ® 57 lispro 57 abatacept 57 bolus dose 57 TIMI 57 oral antidiabetes 57 TYKERB 57 Neupro R 57 randomized #:# 57 azacitidine 57 NAbs 57 anakinra 57 hepatic metastases 57 octreotide acetate 57 MIRAPEX ER 57 anemia hemoglobin 57 SPRYCEL 57 venlafaxine 57 golimumab CNTO 57 secondary efficacy endpoint 57 mg q#h 57 SUTENT 57 GAMMAGARD 57 EUFLEXXA R 57 Randomized Phase 57 log# copies mL 57 unfractionated heparin 57 adriamycin 57 coadministration 57 cell lymphoma CTCL 57 idarubicin 57 pregabalin 57 Hepatotoxicity 57 TMP SMX 57 #mg/m# [002] 57 Thrombotic events 57 CR nPR 57 NYHA Class III 57 plus MTX 57 mcg dose 57 aldosterone antagonists 57 carboplatin paclitaxel 57 basal bolus regimen 57 docetaxel Taxotere R 57 ara C 56 cisplatin vinorelbine 56 ENDOMETRIN 56 EXPAREL TM 56 splenectomized 56 dose cytarabine 56 timepoint 56 q#h 56 fluvastatin 56 aldosterone antagonist 56 fosamprenavir 56 AZILECT 56 polyarticular 56 RSD# oral 56 KAPIDEX 56 PEGylated anti 56 β blocker 56 gadobutrol 56 doxorubicin docetaxel 56 splenectomized patients 56 rosuvastatin Crestor 56 vWD 56 events thrombocytopenia neutropenia 56 INC# 56 Lantus ® 56 HDRS 56 opioid naive 56 Taxotere R 56 median PFS 56 REVLIMID lenalidomide 56 REYATAZ 56 mg tid 56 Peginterferon Alfa 2a 56 alvimopan 56 evaluating REVLIMID 56 SPRYCEL ® 56 Dasatinib 56 INVEGA ™ 56 erlotinib Tarceva ® 56 PRISTIQ 56 plus GP IIb 56 lamivudine 56 FROVA 56 febuxostat 56 Pooled Analysis 56 refractory AML 56 trials RCTs 56 TRANSFORMS 56 imipenem 56 dextromethorphan quinidine 56 recurrent DVT 56 platinum refractory 56 placebo controlled trials 56 generalized tonic clonic seizures 56 CrCl 56 acarbose 56 peginterferon alfa 2a Pegasys 56 coronary stenosis 56 cisplatin gemcitabine 56 efficacy endpoint 56 antiretroviral naive 56 bendamustine 56 NNT = 56 danazol 56 AVODART 56 virologic breakthrough 56 erythema redness 56 receiving prophylactic anticoagulation 56 EPIVIR 56 rash pruritus nausea 56 glatiramer acetate 56 peg IFN 56 VAPRISOL 56 microbiological eradication 56 Renal impairment 56 mCi kg 56 vasomotor symptoms 56 atazanavir 56 mg/# hours 56 Thal Dex 56 bepotastine besilate nasal spray 56 acitretin 56 NPH insulin 56 candidemia 56 fosbretabulin 56 bosutinib 56 mcg mL 56 Non Responders 56 NYHA class 56 beta2 agonist 56 Brief Psychiatric 56 blinded randomized placebo controlled 56 reinfarction 56 cabazitaxel 56 CIMZIA R 56 thromboembolism 56 mg administered orally 56 MULTAQ 56 DU #b 56 QD dosing 56 pegylated alpha interferon 56 deep venous thromboses 56 Mg Uk 56 DexaSite 56 fluticasone 56 prolonged QT interval 56 placebo fluoxetine 56 ceftriaxone 56 T2DM 56 ug dose 56 Taxotere ® 56 esomeprazole Nexium 56 periprocedural 56 methotrexate monotherapy 56 NOXAFIL Oral Suspension 56 histologically confirmed 56 RGT arm 56 eplerenone 56 lymphocytosis 56 Raptiva r 56 pioglitazone HCl 56 GERD symptoms 56 aspirin clopidogrel 56 toxicities 56 lipid lowering agents 56 Hypotension 56 diarrhea headache nausea 56 azathioprine 56 treatment naive genotype 56 nucleoside naive 56 Navelbine 56 painful diabetic neuropathy 56 mg/m2 56 FOLFOX6 56 binary restenosis 56 HMG CoA reductase inhibitors 56 Discontinuation 56 tumor lysis syndrome 56 PEGylated interferon beta 1a 56 ACR Pedi 56 mg subcutaneously 56 multicenter placebo controlled 56 dyspnea 56 sumatriptan naproxen sodium 56 olanzapine Zyprexa 56 lipid parameters 56 Tarceva TM 56 unstable angina UA 56 COPAXONE R 56 telcagepant 56 rosuvastatin #mg 56 FASLODEX 56 mesalamine granules 56 ascending dose 56 proteinuria 56 acute coronary syndromes ACS 56 placebo controlled Phase 56 Butrans 56 malignancy HCM 56 #mg dose [001] 56 Welchol 56 adalimumab Humira 56 isoproterenol 56 mg Pycnogenol 56 metastatic renal cell carcinoma 56 hepatic dysfunction 56 STELARA 56 EDARBI 56 runny nose nasal congestion 56 PsA 56 clodronate 56 Viread Emtriva Sustiva 56 Folfox 56 pheochromocytoma 56 invasive aspergillosis 56 DAPT 56 HCV Genotype 56 AVANDIA 56 TELCYTA 56 HCV genotype 1 56 pegylated interferon alfa 2a 56 Tolvaptan 56 evaluating mipomersen 56 virologic responses 56 oxybutynin 56 cariprazine 56 injected subcutaneously 56 MIRAPEX 56 CYPHER R Sirolimus eluting 56 amphotericin B 56 TMC# C# 56 acute bipolar mania 56 Engerix B 56 dermatologic reactions 56 PegIntron 56 galiximab 56 dopamine partial agonist 56 beta blocker therapy 56 Bezielle 56 systemic embolism 56 thioridazine 56 levofloxacin 56 bortezomib refractory 56 Darunavir 56 palonosetron 56 pharmacodynamic profile 56 etravirine 56 efavirenz EFV 56 #mg QD [001] 56 Cimzia ® 56 MEVACOR 56 nausea dizziness vomiting 56 crizotinib PF # 56 sustained virologic response 56 oral antidiabetic medication 56 Zavesca R 56 APTIVUS ritonavir 56 paroxysmal AF 56 Rating Scale MADRS 56 HbA1c levels 56 SEROQUEL XR 56 TRAIL R1 56 infliximab 56 atherothrombotic events 56 dosing regimens 56 p = NS 56 tricyclic antidepressants 56 tigecycline 56 lenalidomide Revlimid R 56 severe hypoglycemic 56 mucosal inflammation 56 complete remissions 56 NovoLog ® Mix 56 cholinesterase inhibitor 56 biochemical relapse 55 anaphylactic reactions bronchospasm 55 oral prednisone 55 invasive candidiasis 55 Lupuzor ™ 55 mg hydrochlorothiazide 55 GnRH agonists 55 transaminase 55 darbepoetin alfa 55 antihypertensive medications 55 sunitinib Sutent ® 55 6 mercaptopurine 55 diarrhea predominant IBS 55 controlled multicenter